Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Allison Rosenthal appointed Chief Commercial Officer to lead the potential commercial launch of MDMA-assisted therapy if approved by the FDA Coy Stout joins as Vice President of Market Access SAN...
Study completion marks an important next step in the Company's Europe program SAN JOSE, Calif., April 24, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly MAPS Public Benefit Corporation)...
PDUFA date is August 9, 2024 If approved, this would be the first MDMA-assisted therapy and psychedelic-assisted therapy SAN JOSE, Calif., Feb. 9, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly...
Participants with severe PTSD who received MDMA-assisted therapy demonstrated significant improvements in self-experience Improvements in self-compassion associated with MDMA-assisted therapy were...
Funding comes from mission-aligned and institutional investors to support regulatory and pre-launch activities for investigational MDMA-assisted therapy for post-traumatic stress disorder ("PTSD")...
Codes provide avenue for qualified healthcare providers to seek reimbursement for delivering MDMA-assisted therapy if FDA approved SAN JOSE, Calif. , Jan. 2, 2024 /PRNewswire/ -- MAPS Public...
Filing marks first NDA submission for any psychedelic-assisted therapy Submission represents 30 plus years of clinical research into potential use of MDMA-assisted therapy for PTSD NDA includes...
Study met primary and secondary endpoints confirming first Phase 3 study findings MAPP2 population reflects PTSD demographic with approximately half of study participants identifying as racially...
Codes will provide qualified healthcare professionals a means to seek reimbursement for delivering MDMA-assisted therapy if it is approved by the U.S. Food and Drug Administration SAN JOSE, Calif....
Agreement underscores benefit of collaboration to accelerate review of new evidence-based treatment options for people with PTSD Submission of new drug application expected in the second half of 2023